main content start
¿Le gustó este contenido?
Cáncer de mama 6m 44s

Duration of adjuvant trastuzumab in Her2 positive Breast Cancer

Publicado07 Jul 2022
1 Year of Adjuvant Trastuzumab added to chemotherapy has improved DFS & OS compared to no Trastuzumab. 5 non inferiority clinical trials have been conducted to study shorter duration ( 6 months or 9 weeks) of trastuzumab vs 12 months of Trastuzumab to address issue of duration of treatment, concerns with cardiotoxicity & cost of treatment with longer duration. Except PERSEPHONE trial all other clinical trials have not shown benefit compared to 12 months of Trastuzumab. In my practice 1- year of adjuvant Trastuzumab remains standard of care in Her-2 Positive early breast cancer.
6 vs 12 months adjuvant trastuzumab

Disclaimer: The Views/Opinions expressed and/or opinions provided in Videos and other content on MedEnrich Website are those of respective speakers. They do not purport to reflect the opinion or views of Dr.Reddy’s Laboratories Limited or its affiliates (collectively Dr.Reddy’s)in any manner whatsoever and accordingly ,Dr.Reddys does not recommend , endorse or make any representation about the veracity and appropriateness of the views ,opinions/ information on MedEnrich website. Content on MedEnrich website may discuss uses and dosage for therapeutic product that may not have been approved in by the relevant regulatory agencies in your country. Dr.Reddy’s does not support , endorse or encourage any off-label use. Please refer to approved label before prescribing.

Ventajas de registrarse en MedEnrich
Contenido en línea en varios formatos
Contenido personalizado
Acceso ilimitado a todas las funciones
Hi, can I help?
Chat de ayudaX
Equipo de soporte
¡Hola! ¿Cómo puedo ayudarlo/a hoy?
Por favor seleccione alguna de las siguientes opciones.

Buscar información

Problemas con el inicio de sesión o registro

Compartir un comentario